BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

612 related articles for article (PubMed ID: 25739327)

  • 1. [Fertility preservation in breast cancer patients: the state of art in 2014?].
    Comtet M; Sonigo C; Valdelièvre C; Sermondade N; Sifer C; Grynberg M
    Bull Cancer; 2015 May; 102(5):443-53. PubMed ID: 25739327
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Oncofertility and breast cancer].
    Sonigo C; Grynberg M; Bringer S; Sermondade N
    Bull Cancer; 2019 Dec; 106(12S1):S43-S52. PubMed ID: 32008738
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Fertility preservation in adolescents and young adults with cancer].
    Rousset-Jablonski C; Chevillon F; Dhedin N; Poirot C
    Bull Cancer; 2016 Dec; 103(12):1019-1034. PubMed ID: 27817861
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Fertility preservation in women of the childbearing age: Indications and strategies].
    Bénard J; Calvo J; Comtet M; Benoit A; Sifer C; Grynberg M
    J Gynecol Obstet Biol Reprod (Paris); 2016 May; 45(5):424-44. PubMed ID: 27021926
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fertility preservation options in breast cancer patients.
    Kasum M; von Wolff M; Franulić D; Čehić E; Klepac-Pulanić T; Orešković S; Juras J
    Gynecol Endocrinol; 2015; 31(11):846-51. PubMed ID: 26370157
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The case for aromatase inhibitors use in oncofertility patients. Should aromatase inhibitors be combined with gonadotropin treatment in breast cancer patients undergoing ovarian stimulation for fertility preservation prior to chemotherapy? A debate.
    Fatum M; McVeigh E; Child T
    Hum Fertil (Camb); 2013 Dec; 16(4):235-40. PubMed ID: 23863119
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Practical clinical aspects of oocyte vitrification for fertility preservation].
    Courbiere B; Decanter C
    Gynecol Obstet Fertil; 2014 Sep; 42(9):653-6. PubMed ID: 25164159
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fertility after breast cancer treatment.
    Kasum M; Beketić-Orešković L; Peddi PF; Orešković S; Johnson RH
    Eur J Obstet Gynecol Reprod Biol; 2014 Feb; 173():13-8. PubMed ID: 24315568
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New trends in female fertility preservation: in vitro maturation of oocytes.
    Berwanger AL; Finet A; El Hachem H; le Parco S; Hesters L; Grynberg M
    Future Oncol; 2012 Dec; 8(12):1567-73. PubMed ID: 23231518
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Random Start Ovarian Stimulation for Oocyte or Embryo Cryopreservation in Women Desiring Fertility Preservation Prior to Gonadotoxic Cancer Therapy.
    Danis RB; Pereira N; Elias RT
    Curr Pharm Biotechnol; 2017 Nov; 18(8):609-613. PubMed ID: 28786354
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Preservation of fertility in children with cancer].
    de Lambert G; Poirot C; Guérin F; Brugières L; Martelli H
    Bull Cancer; 2015 May; 102(5):436-42. PubMed ID: 25818928
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Freezing oocytes or embryos after controlled ovarian hyperstimulation in cancer patients: the state of the art.
    Bénard J; Duros S; El Hachem H; Sonigo C; Sifer C; Grynberg M
    Future Oncol; 2016 Jul; 12(14):1731-41. PubMed ID: 27184037
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro maturation of human immature oocytes for fertility preservation.
    Chian RC; Uzelac PS; Nargund G
    Fertil Steril; 2013 Apr; 99(5):1173-81. PubMed ID: 23433515
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Fertility preservation strategies in young women in case of breast cancer or hematologic malignancy].
    Decanter C; Robin G
    Gynecol Obstet Fertil; 2013 Oct; 41(10):597-600. PubMed ID: 24094596
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Response to ovarian stimulation is not impacted by a breast cancer diagnosis.
    Quinn MM; Cakmak H; Letourneau JM; Cedars MI; Rosen MP
    Hum Reprod; 2017 Mar; 32(3):568-574. PubMed ID: 28122888
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ovarian reserve and response to stimulation in women undergoing fertility preservation according to malignancy type.
    Lefebvre T; Mirallié S; Leperlier F; Reignier A; Barrière P; Fréour T
    Reprod Biomed Online; 2018 Aug; 37(2):201-207. PubMed ID: 29784618
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Breast cancer and fertility: critical review, considerations and perspectives].
    This P
    Bull Cancer; 2008 Jan; 95(1):17-25. PubMed ID: 18230566
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Systematic proposal of fertility preservation by mature oocyte cryopreservation for recurrent benign ovarian tumors].
    Dadoun Y; Azaïs H; Keller L; d'Orazio E; Collinet P; Decanter C
    Gynecol Obstet Fertil Senol; 2017 Jun; 45(6):359-365. PubMed ID: 28506797
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tamoxifen co-administration during controlled ovarian hyperstimulation for in vitro fertilization in breast cancer patients increases the safety of fertility-preservation treatment strategies.
    Meirow D; Raanani H; Maman E; Paluch-Shimon S; Shapira M; Cohen Y; Kuchuk I; Hourvitz A; Levron J; Mozer-Mendel M; Brengauz M; Biderman H; Manela D; Catane R; Dor J; Orvieto R; Kaufman B
    Fertil Steril; 2014 Aug; 102(2):488-495.e3. PubMed ID: 24934489
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Do controlled ovarian hyperstimulations and cryopreservations promote recurrences after breast cancer?].
    Bergamini ML; Maugard CM; Mathelin C
    Gynecol Obstet Fertil Senol; 2017 Mar; 45(3):172-179. PubMed ID: 28259703
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.